The development of an HIV vaccine is a crucial component required to bring the HIV/AIDS epidemic to an end. Vaccines can be either therapeutic or prophylactic. Therapeutic vaccines are designed to control/clear HIV from already infected individuals whereas prophylactic or preventive vaccines are designed to reduce the risk of infection in people who are not infected with HIV and also to reduce the viral load set point in people infected with HIV. VAX003 and VAX004 trials tested HIV vaccine named AIDSVAX a vaccine consisting B envelope of recombinant gp120 protein. subunits of HIV surface proteins, example gp120 and gp160, made using recombinant DNA technology. AIDSVAX used in the VAX003 and VAX004 trials was based on recombinant gp120 (rgp120).
A journal is a periodical publication intended to further progress of science, usually by reporting new research. Most journals are highly specialized, although some of the oldest journals publish articles, reviews, editorials, short communications, letters, and scientific papers across a wide range of scientific fields. Journals contain articles that peer reviewed, in an attempt to ensure that articles meet the journal's standards of quality, and scientific validity. Each such journal article becomes part of the permanent scientific record.
Last date updated on November, 2020